Evidence map›Paper›PMID 41317315›Full record

ArticleThe journal of pathology. Clinical research2026

Development of a decision tree diagram for classifying study designs in tumour pathology research: a multidisciplinary approach.

Oana M Craciun, Ester García-Ovejero, Fiona Campbell, Marina Montes-Mota, Stefan Holdenrieder, Inga Trulson, Karolina Worf, Sophie Gabriel, Magdalena Kowalewska, Irmina Michalek and 16 more

Abstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Oana M Craciun *National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-0585-1950
Ester García-Ovejero *National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Fiona CampbellPopulation Health Sciences, Newcastle University, Newcastle Upon Tyne, UK.
Marina Montes-MotaNational Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Stefan HoldenriederInstitute of Laboratory Medicine, TUM University Hospital, German Heart Centre, Munich, Germany.
Inga TrulsonInstitute of Laboratory Medicine, TUM University Hospital, German Heart Centre, Munich, Germany.
Karolina WorfInstitute of Laboratory Medicine, TUM University Hospital, German Heart Centre, Munich, Germany.
Sophie GabrielInstitute of Laboratory Medicine, TUM University Hospital, German Heart Centre, Munich, Germany.
Magdalena KowalewskaDepartment of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Irmina MichalekDepartment of Cancer Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Kateryna MaslovaDepartment of Cancer Biology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Lukasz TaraszkiewiczDepartment of Cancer Biology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Javier Del ÁguilaNational Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Richard CollingNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Puay Hoon TanDepartment of Pathology, Luma Medical Centre, Singapore.
Gabrielle Goldman-LévyInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Christine GiesenInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Ramon Cierco JimenezInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Dilani LokuhettyInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Ian A CreeInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Iciar IndaveInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Beatriz Pérez GómezNational Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Magdalena ChechlińskaDepartment of Cancer Biology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Marina Pollán Santamaría *National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Elena Plans-Beriso *National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
WCT EVI MAP Project Team

Funding

European Union, HORIZON-HLTH-2021-CARE-05 101057127Innovate UK 10040375World Health Organization 001
6 · The paper itself

Abstract

The World Health Organization (WHO) Classification of Tumours: A Living Evidence Gap Map by Tumour Type (WCT EVI MAP) project aims to develop Evidence Gap Maps of the available evidence, primarily to inform the WHO Classification of Tumours. The project, covering all tumour types, faces the challenge of reviewing a huge number of studies by reviewers from multiple backgrounds. The aim was to develop a decision tree (DT) diagram for classifying study designs reporting on tumour pathology studies, in order to support the decision-making process when assigning evidence levels across various disciplines. A modified consensus process, incorporating stakeholder workshops, was conducted in three phases: (1) development of the initial DT diagram draft (literature review and expert evaluation); (2) iterative reviews with project partners; and (3) testing the advanced DT diagram version with several sets of references to refine critical points. A total of 368 records were used for training throughout the entire process. Consensus was achieved when classifications could categorise studies consistently without causing discordance in new example sets. A DT diagram and its Glossary of Operational Definitions with 27 decision nodes and 26 categories were developed. The DT diagram is organised into six sections: WCT EVI MAP selection criteria, evidence synthesis, basic research related studies, descriptive studies, observational and experimental studies, and diagnostic test studies. The DT diagram is a valuable tool for the project's needs, successfully integrating diverse disciplinary perspectives for classifying evidence in tumour pathology research according to study design. It lays the foundation for future advancements in evidence mapping and classification within tumour pathology and related disciplines.

Indexed as

Biomedical ResearchDecision TreesNeoplasmsResearch DesignConsensusHumansdecision treesepidemiologic study characteristicsevidence‐based medicinemethodsneoplasmsreview literature as topicstudy characteristicsWCTWCT EVI MAP projectWorld Classification of Tumours

Identifiers

PMID41317315
PMCPMC12664524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.